BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/14/2019 8:35:15 AM | Browse: 741 | Download: 1178
 |
Received |
|
2019-02-21 00:21 |
|
Peer-Review Started |
|
2019-02-22 07:05 |
|
To Make the First Decision |
|
2019-05-09 00:29 |
|
Return for Revision |
|
2019-05-09 02:08 |
|
Revised |
|
2019-05-15 01:50 |
|
Second Decision |
|
2019-05-22 09:22 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-05-23 13:14 |
|
Articles in Press |
|
2019-05-23 13:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-06-12 08:59 |
|
Publish the Manuscript Online |
|
2019-06-14 08:35 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ravi Kant, Kashif M Munir, Arshpreet Kaur and Vipin Verma |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ravi Kant, MD, Associate Professor, Division of Endocrinology, Diabetes and Nutrition, Medical University of South Carolina/Anmed Campus, 2000 E Greenville St., Suite # 3100, Anderson, SC 29621, United States. kant.ravi.md@gmail.com |
| Key Words |
Newer antidiabetic medications; Glucagon-like peptide-1 receptor agonist; Sodium-glucose cotransporter-2 inhibitors; Type 2 diabetes mellitus; Macrovascular complications; Cardiovascular outcome trials; Major cardiovascular events; Heart failure; Prevention of heart disease |
| Core Tip |
Multiple cardiovascular (CV) outcome trials performed mainly to meet regulatory requirements by United States Food and Drug Administration have provided very important findings on CV safety and efficacy of newer anti-diabetic drugs. All drugs in glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT-2)-inhibitor classes have shown to be CV safe with heterogeneous results on CV efficacy. Abundance of data and heterogeneity in CV outcome trials results can make it difficult for clinicians to stay updated with all the recent evidence. The scope of this comprehensive review will focus on all major CV outcome studies evaluating CV safety and efficacy of GLP-1 RAs and SGLT-2 inhibitors. |
| Publish Date |
2019-06-14 08:35 |
| Citation |
Kant R, Munir KM, Kaur A, Verma V. Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications. World J Diabetes 10(6): 324-332 |
| URL |
https://www.wjgnet.com/1948-9358/full/v10/i6/324.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v10.i6.324 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
